Jan 9 (Reuters) - NEWRON PHARMACEUTICALS SPA:
* ANNOUNCES INITIATION OF NEW CLINICAL TRIAL WITH EVENAMIDE IN PATIENTS WITH SCHIZOPHRENIA, FOLLOWING APPROVAL OF PLAN BY FDA
* EXPECTS INITIAL RESULTS FROM ADDITIONAL STUDIES IN RATS AND HUMANS IN Q3 2020
* WE EXPECT TO SUBMIT INITIAL RESULTS TO FDA IN Q3 2020, AND RESULTS FROM NEXT STUDY IN PATIENTS IN Q4 2020
* ACCEPTANCE OF RESULTS FROM STUDIES IN HUMANS AND TOXICOLOGY STUDIES TO ALLOW TO START PHASE III CLINICAL PROGRAM SHORTLY THEREAFTER Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.